Evidence map›Paper›PMID 41619085›Full record

ReviewInflammopharmacology2026

Cannabinoid type 2 receptor crosstalk and microglial plasticity-shaping the balance between neuroinflammation and repair.

Shlok Bodke, Lokesh Kumar Bhatt

Abstract readReview
PubMed Publisher
In one paragraph

Review in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Shlok BodkeDepartment of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Vile Parle (W), Vile Parle (W), Mumbai, India.
Lokesh Kumar BhattDepartment of Pharmacology, SVKM's Dr. Bhanuben Nanavati College of Pharmacy, Vile Parle (W), Vile Parle (W), Mumbai, India. lokesh.bhatt@bncp.ac.in.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microglial cells play a pivotal role in the different CNS related conditions as they have the power to destruct as well protect the Central Nervous System. Depending on the environment they are in, they respond to different stimuli and carry out a function. Majority of the cases, the microglial cells are activated which cause inflammation to a very large extent and for a prolonged period of time which causes the various signs and symptoms of the neurodegenerative disorders. Cannabinoid Type-2 (CB2) receptor crosstalk is a key modulator of microglial plasticity, influencing both pro-inflammatory and anti-inflammatory states in the brain. Activation of CB2 receptors in microglia can suppress neurotoxic inflammation, promote anti-inflammatory phenotypes, and facilitate microglial migration and environmental surveillance. By shifting microglial polarization away from pro-inflammatory states, CB2 stimulation helps control neuroinflammation and supports tissue repair in neurodegenerative and neuroinflammatory conditions. This intricate crosstalk highlights CB2 as a promising therapeutic target for managing central nervous system dysfunctions mediated by microglial activity. The present review discusses CB2 receptor crosstalk and its role in microglial plasticity and neuroinflammation.

Indexed as

Cell PlasticityInflammationMicrogliaNeuroinflammatory DiseasesReceptor, Cannabinoid, CB2Receptor Cross-TalkAnimalsHumansNeurodegenerative DiseasesNeuronal PlasticityReceptor, Cannabinoid, CB2Cannabinoid type-2 (CB2) receptorMicroglialMicroglial plasticityNeuroinflammation

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.